Related Experiment Video

Updated: Aug 11, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

The antitumor agent tamoxifen inhibits breakdown of polyphosphoinositides in GH4C1 cells

Z Y Friedman1

  • 1Department of Biological Chemistry, Hebrew University of Jerusalem, Israel.

The Journal of Pharmacology and Experimental Therapeutics
|October 1, 1994
PubMed

Insights

Tamoxifen exhibits estrogen-independent anticancer effects by inhibiting phospholipase C (PLC). This drug blocks phosphoinositide breakdown, potentially contributing to its antiproliferative activity in cancer treatment.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Tamoxifen is primarily known as an antiestrogenic drug for breast cancer treatment.
  • Emerging evidence suggests tamoxifen possesses estrogen-independent antiproliferative effects.
  • Tamoxifen has been shown to stimulate phosphatidylinositol kinase and phosphatidylinositol-4-phosphate kinase activities.

Purpose of the Study:

  • To investigate the effect of tamoxifen on phospholipase C (PLC) activity.
  • To explore the role of PLC inhibition in tamoxifen's estrogen-independent anticancer properties.

Main Methods:

  • Assessing the impact of tamoxifen on inositol phosphate accumulation in GH4C1 cells stimulated by thyrotropin-releasing hormone or bombesin.
  • Measuring phosphoinositide breakdown in GH4C1 membrane preparations stimulated by guanosine-5'-O-(3-thiotriphosphate) or Ca++.
  • Evaluating PLC activity in an in vitro system using solubilized enzyme preparations and exogenous substrate.

Main Results:

  • Tamoxifen inhibited phospholipase C (PLC) activity.
  • Tamoxifen blocked inositol phosphate accumulation in whole cells and phosphoinositide breakdown in membrane preparations.
  • No other enzymes in the phosphoinositide breakdown cascade were affected by tamoxifen.

Conclusions:

  • Tamoxifen's inhibition of phospholipase C (PLC) activity is a key finding.
  • Blocking phosphoinositide breakdown by tamoxifen may contribute to its estrogen-independent anticancer effects.
  • Further research into PLC's role in cell proliferation is warranted in the context of tamoxifen's mechanism of action.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...